• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Thromb Thrombolysis . Von Willebrand factor with increased binding capacity is associated with reduced platelet aggregation but enhanced agglutina

tetano

Editor, Senior Moderator
J Thromb Thrombolysis


. 2021 Jan 2.
doi: 10.1007/s11239-020-02339-6. Online ahead of print.
Von Willebrand factor with increased binding capacity is associated with reduced platelet aggregation but enhanced agglutination in COVID-19 patients: another COVID-19 paradox?


Franco Ruberto[SUP] 1 [/SUP], Antonio Chistolini[SUP] 2 [/SUP], Mariaignazia Curreli[SUP] 3 [/SUP], Giacomo Frati[SUP] 4 5 [/SUP], Antonino G M Marullo[SUP] 4 [/SUP], Giuseppe Biondi-Zoccai[SUP] 4 6 [/SUP], Massimo Mancone[SUP] 7 [/SUP], Sebastiano Sciarretta[SUP] 4 5 [/SUP], Fabio Miraldi[SUP] 7 [/SUP], Francesco Alessandri[SUP] 1 [/SUP], Giancarlo Ceccarelli[SUP] 8 [/SUP], Francesco Barone[SUP] 2 [/SUP], Cristina Santoro[SUP] 2 [/SUP], Domenico Alvaro[SUP] 9 [/SUP], Francesco Pugliese[SUP] 1 [/SUP], Fabio M Pulcinelli[SUP] 10 [/SUP], Policlinico Umberto I COVID-19 Group



Collaborators, Affiliations

Abstract

Patients with Coronavirus-associated disease-2019 (COVID-19) display alterations of the hemostatic system and the presence of a prothrombotic status frequently leading to vascular complications. However, the impact of COVID-19 on platelet activity, aggregation and agglutination still needs to be clarified. We measured total levels of von Willebrand factor (vWF) and vWF binding to the platelet glycoprotein (Gp) complex (GPIb-IX-V), in a cohort of COVID-19 patients admitted to the intensive care unit of our Institution. Moreover, we evaluated platelet aggregation in response to agonists (ADP, collagen, arachidonic acid) and platelet agglutination in response to ristocetin. We found that levels of vWF antigen and the active form of vWF binding to platelets (vWF:RCo), were markedly increased in these patients. These results were associated with higher agglutination rates induced by ristocetin, thereby indirectly indicating an increased capability of vWF to bind to platelets. Conversely, we found that platelet aggregation in response to both ADP and collagen was lower in COVID-19 patients compared to healthy volunteers. This study shows that COVID-19 is associated with increased vWF-induced platelet agglutination but reduced platelet responsivity to aggregation stimuli. Our findings have translational relevance since platelet adhesion to vWF may represent a marker to predict possible complications and better delineate therapeutic strategies in COVID-19 patients.

Keywords: Covid 19; Platelets; vonWillebrand factor.
 
Back
Top Bottom